Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120048 | 0.85 | CTBP2 (0.51) | CTBP2ALDH1A1TSHRPOLQTRPM8 | |
| SCHEMBL2393306 | 0.81 | ALDH1A1 (0.42) | ALDH1A1POLQSLC6A9 | |
| SCHEMBL8720333 | 0.81 | KMT2A (0.51) | ALDH1A1POLQNR4A2CHRM1 | |
| SCHEMBL9447453 | 0.80 | PTGS2 (0.54) | FFAR1FFAR4CTBP2ALDH1A1PTGS2 | |
| SCHEMBL9890710 | 0.79 | FFAR1 (0.43) | FFAR1FFAR4CTBP2ALDH1A1PTGS2 | |
| SCHEMBL12202180 | 0.78 | POLQ (0.57) | ALDH1A1POLQACHEHPGD | |
| SCHEMBL24802429 | 0.77 | ALDH1A1 (0.45) | CTBP2ALDH1A1TSHRPTGS2BCHE | |
| SCHEMBL11327583 | 0.77 | TAAR1 (0.48) | ALDH1A1TSHRPOLQNR4A2HPGD | |
| SCHEMBL8566845 | 0.76 | CD274 (0.53) | ALDH1A1NR4A2 | |
| SCHEMBL9890711 | 0.76 | HPGD (0.42) | FFAR1FFAR4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR1 223/4885FFAR4 621/4885TACR1 2276/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR1 223/4885FFAR4 621/4885TACR1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.